Cargando…

Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report

RATIONALE: Fluoropyrimidine-induced cardiotoxicity is a rare but potentially serious toxicity. The most common symptom is anginal chest pain. PATIENT CONCERNS: A 35-year-old woman was diagnosed with rectal cancer with metastasis to the liver. DIAGNOSIS: A computed tomography scan showed a 9.3 × 4.5-...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Tao, Ouyang, Yulu, Tong, Kanger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336628/
https://www.ncbi.nlm.nih.gov/pubmed/30633206
http://dx.doi.org/10.1097/MD.0000000000014057
_version_ 1783388081852776448
author Peng, Tao
Ouyang, Yulu
Tong, Kanger
author_facet Peng, Tao
Ouyang, Yulu
Tong, Kanger
author_sort Peng, Tao
collection PubMed
description RATIONALE: Fluoropyrimidine-induced cardiotoxicity is a rare but potentially serious toxicity. The most common symptom is anginal chest pain. PATIENT CONCERNS: A 35-year-old woman was diagnosed with rectal cancer with metastasis to the liver. DIAGNOSIS: A computed tomography scan showed a 9.3 × 4.5-cm predominantly hypodense lesion within the left lobe of the liver and thickening of the rectum. Liver biopsy showed moderately differentiated adenocarcinoma with necrosis involving the liver parenchyma, and immunohistochemistry for mismatch repair proteins indicated that the tumor was positive for MutL Homolog 1, MutS Homolog 2, MutS Homolog 6, and Protein Homolog 2. Rectal biopsy indicated moderately differentiated adenocarcinoma. INTERVENTIONS: She received chemotherapy of fluorouracil 1600 mg/m(2), leucovorin 500 mg/m(2), and irinotecan 100 mg/m(2) every week. During the second cycle of chemotherapy, she developed severe anginal chest pain. We replaced fluorouracil with capecitabine 1500 mg (3 pills) a day every 2 weeks, with 1 week off, with irinotecan 100 mg/m(2) on day 1 and bevacizumab 5 mg/kg at 200 ml/h for 30 min every 2 weeks. She was treated with chemotherapy for approximately 6 months. OUTCOMES: The liver lesion showed a significant response to chemotherapy, so she underwent resection of the liver tumor and rectum. After the surgery, she received radiation therapy to the rectal area, and 3 months of chemotherapy were administered prior to colostomy reversal. LESSONS: Although the mechanism of fluoropyrimidine-induced cardiotoxicity is still uncertain, our case provides clinical evidence that cardiotoxicity could be a dose-related complication. Reducing the dose of fluoropyrimidine should be considered as a strategy after fluoropyrimidine-induced cardiotoxicity. However, this must be discussed with a multidisciplinary team including oncologists and cardiologists. Close monitoring of serial biomarkers and echocardiography are necessary for early diagnosis of cardiotoxicity.
format Online
Article
Text
id pubmed-6336628
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-63366282019-01-24 Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report Peng, Tao Ouyang, Yulu Tong, Kanger Medicine (Baltimore) Research Article RATIONALE: Fluoropyrimidine-induced cardiotoxicity is a rare but potentially serious toxicity. The most common symptom is anginal chest pain. PATIENT CONCERNS: A 35-year-old woman was diagnosed with rectal cancer with metastasis to the liver. DIAGNOSIS: A computed tomography scan showed a 9.3 × 4.5-cm predominantly hypodense lesion within the left lobe of the liver and thickening of the rectum. Liver biopsy showed moderately differentiated adenocarcinoma with necrosis involving the liver parenchyma, and immunohistochemistry for mismatch repair proteins indicated that the tumor was positive for MutL Homolog 1, MutS Homolog 2, MutS Homolog 6, and Protein Homolog 2. Rectal biopsy indicated moderately differentiated adenocarcinoma. INTERVENTIONS: She received chemotherapy of fluorouracil 1600 mg/m(2), leucovorin 500 mg/m(2), and irinotecan 100 mg/m(2) every week. During the second cycle of chemotherapy, she developed severe anginal chest pain. We replaced fluorouracil with capecitabine 1500 mg (3 pills) a day every 2 weeks, with 1 week off, with irinotecan 100 mg/m(2) on day 1 and bevacizumab 5 mg/kg at 200 ml/h for 30 min every 2 weeks. She was treated with chemotherapy for approximately 6 months. OUTCOMES: The liver lesion showed a significant response to chemotherapy, so she underwent resection of the liver tumor and rectum. After the surgery, she received radiation therapy to the rectal area, and 3 months of chemotherapy were administered prior to colostomy reversal. LESSONS: Although the mechanism of fluoropyrimidine-induced cardiotoxicity is still uncertain, our case provides clinical evidence that cardiotoxicity could be a dose-related complication. Reducing the dose of fluoropyrimidine should be considered as a strategy after fluoropyrimidine-induced cardiotoxicity. However, this must be discussed with a multidisciplinary team including oncologists and cardiologists. Close monitoring of serial biomarkers and echocardiography are necessary for early diagnosis of cardiotoxicity. Wolters Kluwer Health 2019-01-11 /pmc/articles/PMC6336628/ /pubmed/30633206 http://dx.doi.org/10.1097/MD.0000000000014057 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle Research Article
Peng, Tao
Ouyang, Yulu
Tong, Kanger
Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report
title Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report
title_full Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report
title_fullStr Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report
title_full_unstemmed Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report
title_short Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report
title_sort rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: a case report
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336628/
https://www.ncbi.nlm.nih.gov/pubmed/30633206
http://dx.doi.org/10.1097/MD.0000000000014057
work_keys_str_mv AT pengtao rechallengecapecitabineafterfluoropyrimidineinducedcardiotoxicityinrectalcanceracasereport
AT ouyangyulu rechallengecapecitabineafterfluoropyrimidineinducedcardiotoxicityinrectalcanceracasereport
AT tongkanger rechallengecapecitabineafterfluoropyrimidineinducedcardiotoxicityinrectalcanceracasereport